Copyright Reports & Markets. All rights reserved.

Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Insights, Forecast to 2025

Request for Sample of this report
Buy now

Table of Contents

    1 Study Coverage

    • 1.1 Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Product
    • 1.2 Market Segments
    • 1.3 Key Manufacturers Covered
    • 1.4 Market by Type
      • 1.4.1 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size Growth Rate by Product
      • 1.4.2 Corticosteroids
      • 1.4.3 Intravenous Immunoglobulin (IVIG)
      • 1.4.4 Anti-D Immunoglobulin
      • 1.4.5 Thrombopoietin Receptor Agonists (TPO-RA)
      • 1.4.6 Others
    • 1.5 Market by End User
      • 1.5.1 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size Growth Rate by End User
      • 1.5.2 Hospitals
      • 1.5.3 Clincs
      • 1.5.4 Others
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Executive Summary

    • 2.1 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size
      • 2.1.1 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue 2014-2025
      • 2.1.2 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales 2014-2025
    • 2.2 Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Growth Rate by Regions
      • 2.2.1 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales by Regions
      • 2.2.2 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Regions

    3 Breakdown Data by Manufacturers

    • 3.1 Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales by Manufacturers
      • 3.1.1 Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales by Manufacturers
      • 3.1.2 Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Market Share by Manufacturers
      • 3.1.3 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Concentration Ratio (CR5 and HHI)
    • 3.2 Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Manufacturers
      • 3.2.1 Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Manufacturers (2014-2019)
      • 3.2.2 Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Share by Manufacturers (2014-2019)
    • 3.3 Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Price by Manufacturers
    • 3.4 Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Manufacturing Base Distribution, Product Types
      • 3.4.1 Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Manufacturers Manufacturing Base Distribution, Headquarters
      • 3.4.2 Manufacturers Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Product Type
      • 3.4.3 Date of International Manufacturers Enter into Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market
    • 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Product

    • 4.1 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales by Product
    • 4.2 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Product
    • 4.3 Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Price by Product

    5 Breakdown Data by End User

    • 5.1 Overview
    • 5.2 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Breakdown Data by End User

    6 North America

    • 6.1 North America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics by Countries
      • 6.1.1 North America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales by Countries
      • 6.1.2 North America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Countries
      • 6.1.3 United States
      • 6.1.4 Canada
      • 6.1.5 Mexico
    • 6.2 North America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics by Product
    • 6.3 North America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics by End User

    7 Europe

    • 7.1 Europe Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics by Countries
      • 7.1.1 Europe Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales by Countries
      • 7.1.2 Europe Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Countries
      • 7.1.3 Germany
      • 7.1.4 France
      • 7.1.5 UK
      • 7.1.6 Italy
      • 7.1.7 Russia
    • 7.2 Europe Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics by Product
    • 7.3 Europe Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics by End User

    8 Asia Pacific

    • 8.1 Asia Pacific Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics by Countries
      • 8.1.1 Asia Pacific Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales by Countries
      • 8.1.2 Asia Pacific Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Countries
      • 8.1.3 China
      • 8.1.4 Japan
      • 8.1.5 Korea
      • 8.1.6 India
      • 8.1.7 Australia
      • 8.1.8 Indonesia
      • 8.1.9 Malaysia
      • 8.1.10 Philippines
      • 8.1.11 Thailand
      • 8.1.12 Vietnam
      • 8.1.13 Singapore
    • 8.2 Asia Pacific Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics by Product
    • 8.3 Asia Pacific Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics by End User

    9 Central & South America

    • 9.1 Central & South America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics by Countries
      • 9.1.1 Central & South America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales by Countries
      • 9.1.2 Central & South America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Countries
      • 9.1.3 Brazil
    • 9.2 Central & South America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics by Product
    • 9.3 Central & South America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics by End User

    10 Middle East and Africa

    • 10.1 Middle East and Africa Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics by Countries
      • 10.1.1 Middle East and Africa Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales by Countries
      • 10.1.2 Middle East and Africa Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Countries
      • 10.1.3 GCC Countries
      • 10.1.4 Turkey
      • 10.1.5 Egypt
      • 10.1.6 South Africa
    • 10.2 Middle East and Africa Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics by Product
    • 10.3 Middle East and Africa Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics by End User

    11 Company Profiles

    • 11.1 Roch
      • 11.1.1 Roch Company Details
      • 11.1.2 Company Business Overview
      • 11.1.3 Roch Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales, Revenue and Gross Margin (2014-2019)
      • 11.1.4 Roch Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Products Offered
      • 11.1.5 Roch Recent Development
    • 11.2 Amgen Inc
      • 11.2.1 Amgen Inc Company Details
      • 11.2.2 Company Business Overview
      • 11.2.3 Amgen Inc Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales, Revenue and Gross Margin (2014-2019)
      • 11.2.4 Amgen Inc Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Products Offered
      • 11.2.5 Amgen Inc Recent Development
    • 11.3 Grifols Biologicals Inc.
      • 11.3.1 Grifols Biologicals Inc. Company Details
      • 11.3.2 Company Business Overview
      • 11.3.3 Grifols Biologicals Inc. Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales, Revenue and Gross Margin (2014-2019)
      • 11.3.4 Grifols Biologicals Inc. Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Products Offered
      • 11.3.5 Grifols Biologicals Inc. Recent Development
    • 11.4 GlaxoSmithKline Plc
      • 11.4.1 GlaxoSmithKline Plc Company Details
      • 11.4.2 Company Business Overview
      • 11.4.3 GlaxoSmithKline Plc Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales, Revenue and Gross Margin (2014-2019)
      • 11.4.4 GlaxoSmithKline Plc Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Products Offered
      • 11.4.5 GlaxoSmithKline Plc Recent Development

    12 Future Forecast

    • 12.1 Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Forecast by Regions
      • 12.1.1 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Forecast by Regions 2019-2025
      • 12.1.2 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Forecast by Regions 2019-2025
    • 12.2 Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Forecast by Product
      • 12.2.1 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Forecast by Product 2019-2025
      • 12.2.2 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Forecast by Product 2019-2025
    • 12.3 Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Forecast by End User
    • 12.4 North America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Forecast
    • 12.5 Europe Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Forecast
    • 12.6 Asia Pacific Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Forecast
    • 12.7 Central & South America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Forecast
    • 12.8 Middle East and Africa Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Forecast

    13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

    • 13.1 Market Opportunities and Drivers
    • 13.2 Market Challenges
    • 13.3 Market Risks/Restraints
    • 13.4 Macroscopic Indicators

    14 Value Chain and Sales Channels Analysis

    • 14.1 Value Chain Analysis
    • 14.2 Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Customers
    • 14.3 Sales Channels Analysis
      • 14.3.1 Sales Channels
      • 14.3.2 Distributors

    15 Research Findings and Conclusion

      16 Appendix

      • 16.1 Research Methodology
        • 16.1.1 Methodology/Research Approach
        • 16.1.2 Data Source
      • 16.2 Author Details

      ITP (idiopathic thrombocytopenic purpura) is a rare disease with low affliction rates. This disease leads to excessive bruising or bleeding due to the lack of blood platelets. It is also known as immune thrombocytopenia and can affect children and adults alike.
      Increasing demand for combination therapies therapy is expected to fuel the future growth of the ITP therapeutics market. Clinical evidence suggest that combination therapies entail relatively lower side effects, are cost effective and display higher response rates in patients.
      The global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics market based on company, product type, end user and key regions.

      This report studies the global market size of Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics in these regions.
      This research report categorizes the global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics market by top players/brands, region, type and end user. This report also studies the global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

      The following manufacturers are covered in this report, with sales, revenue, market share for each company:
      Roch
      Amgen Inc
      Grifols Biologicals Inc.
      GlaxoSmithKline Plc

      Market size by Product
      Corticosteroids
      Intravenous Immunoglobulin (IVIG)
      Anti-D Immunoglobulin
      Thrombopoietin Receptor Agonists (TPO-RA)
      Others
      Market size by End User
      Hospitals
      Clincs
      Others

      Market size by Region
      North America
      United States
      Canada
      Mexico
      Asia-Pacific
      China
      India
      Japan
      South Korea
      Australia
      Indonesia
      Singapore
      Malaysia
      Philippines
      Thailand
      Vietnam
      Europe
      Germany
      France
      UK
      Italy
      Spain
      Russia
      Central & South America
      Brazil
      Rest of Central & South America
      Middle East & Africa
      GCC Countries
      Turkey
      Egypt
      South Africa

      The study objectives of this report are:
      To study and analyze the global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
      To understand the structure of Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics market by identifying its various subsegments.
      To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
      Focuses on the key global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
      To project the value and sales volume of Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics submarkets, with respect to key regions.
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

      In this study, the years considered to estimate the market size of Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now